Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
Total Valuation
Crescent Biopharma has a market cap or net worth of $312.22M. The enterprise value is $121.06M.
Market Cap$312.22M
Enterprise Value$121.06M
Share Statistics
Crescent Biopharma has 27,556,767 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,556,767
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -73.60%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-73.60%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee264.49K
Profits Per Employee-3.66M
Employee Count41
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is -0.00342.
PE Ratio―
PS Ratio113.89
PB Ratio6.08
Price to Fair Value6.08
Price to FCF-17.05
Price to Operating Cash Flow-52.05
PEG Ratio-0.00342
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 10.84M and earned -149.94M in profits. Earnings per share was -14.78.
Revenue10.84M
Gross Profit10.76M
Operating Income-152.63M
Pretax Income-151.94M
Net Income-149.94M
EBITDA-149.67M
Earnings Per Share (EPS)-14.78
Cash Flow
In the last 12 months, operating cash flow was -22.58M and capital expenditures -808.00K, giving a free cash flow of -23.39M billion.
Operating Cash Flow-22.58M
Free Cash Flow-23.39M
Free Cash Flow per Share-0.85
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
Dividend Per Share$0.24
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-58.42%
50-Day Moving Average11.25
200-Day Moving Average13.48
Relative Strength Index (RSI)51.62
Average Volume (3m)145.41K
Important Dates
Crescent Biopharma upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Crescent Biopharma as a current ratio of 6.56, with Debt / Equity ratio of 0.81%
Current Ratio6.56
Quick Ratio6.56
Debt to Market Cap<0.01
Net Debt to EBITDA1.41
Interest Coverage Ratio-69.85
Taxes
In the past 12 months, Crescent Biopharma has paid -2.00M in taxes.
Income Tax-2.00M
Effective Tax Rate0.01
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is -6.84, with an EV/FCF ratio of -14.13.
EV to Sales94.38
EV to EBITDA-6.84
EV to Free Cash Flow-14.13
EV to Operating Cash Flow-14.31
Balance Sheet
Crescent Biopharma has $213.19M in cash and marketable securities with $1.64M in debt, giving a net cash position of $211.55M billion.
Cash & Marketable Securities$213.19M
Total Debt$1.64M
Net Cash$211.55M
Net Cash Per Share$7.68
Tangible Book Value Per Share$1.95
Margins
Gross margin is 95.93%, with operating margin of -1407.52%, and net profit margin of -1382.72%.
Gross Margin95.93%
Operating Margin-1407.52%
Pretax Margin-1401.16%
Net Profit Margin-1382.72%
EBITDA Margin-1380.24%
EBIT Margin-1381.01%
Analyst Forecast
The average price target for Crescent Biopharma is $28.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$28.20
Price Target Upside148.90% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-0.58%